Neoadjuvant therapy in localized prostate cancer before surgery and radiotherapy

Mouraviev, Vladimir

doi:10.1097/00042307-199809000-00004

Current Opinion in Urology

1998

DOI: 10.1097/00042307-199809000-00004

|View full text |Cite

Neoadjuvant therapy in localized prostate cancer before surgery and radiotherapy

Vladimir Mouraviev¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2003

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is an important part of patients' decision processes. 25,26 A large cross-sectional study involving more than 1000 patients who had received a prostatectomy, brachytherapy, or 3-D conformal radiation within the previous 4 years was conducted. Men in the community without prostate carcinoma served as age-matched control individuals.…”

mentioning

confidence: 99%

Disease‐specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three‐dimensional conformal radiotherapy

Staff

Salner

Bohannon

et al. 2003

Cancer

View full text Add to dashboard Cite

BACKGROUNDApproximately 189,000 men are diagnosed with prostate carcinoma each year and more than 1 million are living with the disease. Good prognoses and undesirable sequelae accompany each of several available primary and adjuvant treatment options. The current study explored the effects of primary three‐dimensional conformal radiotherapy with or without neoadjuvant hormonal therapy on urinary, bowel, and sexual symptoms and health‐related quality of life (HRQOL).METHODSA prospective, repeated‐measures design study included 100 patients. Data from the Medical Outcomes Study Short Form Health Survey (a measure of general HRQOL) and a 12‐item symptom questionnaire were collected before the start of radiotherapy, approximately 1–3 months after completion of treatment, and again approximately 5–10 months after completion of treatment for follow‐up.RESULTSPatients reported few urinary symptoms after treatment. Bowel frequency and urgency were reported more frequently posttreatment and at follow‐up. Erectile difficulties, which were common pretreatment, were reported with increased frequency posttreatment and at follow‐up. General HRQOL scores were higher than age‐related general population norms for men at all three data collection times, but there were significant losses posttreatment for patients' physical functioning and vitality. At the 5–10‐month follow‐up, physical functioning remained lower but vitality scores regained some of the losses. A more extended follow‐up is needed. Neoadjuvant therapy, which was received before the pretreatment data collection, had a deleterious effect on erectile functioning but no interactive effects with the radiotherapy on symptoms or HRQOL.CONCLUSIONSAlthough patients with a diagnosis of prostate carcinoma experienced increased bowel and sexual dysfunction and decreased vitality after radiotherapy, their HRQOL scores remained at or above age‐related general population norms. Cancer 2003. © 2003 American Cancer Society.

show abstract

mentioning

confidence: 99%

Disease‐specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three‐dimensional conformal radiotherapy

Staff

Salner

Bohannon

et al. 2003

Cancer

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Neoadjuvant therapy in localized prostate cancer before surgery and radiotherapy

Cited by 1 publication

References 31 publications

Disease‐specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three‐dimensional conformal radiotherapy

Disease‐specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three‐dimensional conformal radiotherapy

Contact Info

Product

Resources

About